#$KZIA
LightNews LightNews
smcapstrategist.bsky.social
Small-cap stocks in new downward trend with average directional index, Tue Feb 10th - #$LFWD #$NEXM #$TC #$SKIN #$REFI #$RBBN #$PPBT #$NUTX #$KZIA #$BIRD #$AOSL #$KREF #$FIGS #$COOK - More: crystalequityresearch.com/trade-alerts... - #smallcap
Trade Alerts, Tuesday February 10, 2026 – Crystal Equity Research
crystalequityresearch.com
February 10, 2026 at 11:32 PM
liquiditynews.bsky.social
Trading Resumed for $KZIA Kazia Therapeutics Limited ADS | at 16:00:00 ET on NASDAQ | 2026-01-02
January 2, 2026 at 9:03 PM
liquiditynews.bsky.social
Trading Halted for $KZIA Kazia Therapeutics Limited ADS | at 15:45:56 ET on NASDAQ | Volatility Trading Pause | 2026-01-02
January 2, 2026 at 8:48 PM
handle.invalid
🚀 Exciting times for #KZIA! Trading at $9.83, it's riding a bullish wave above its 10-day SMA & 20-day EMA. With positive MACD and RSI at 57, there's room to grow! 🎯 Target: $10.50-$11.00. Volatility is high, so stay sharp! 📈 #FeetrAI #StockMarket #InvestSmart
December 2, 2025 at 8:01 PM
liquiditynews.bsky.social
Trading Resumed for $KZIA Kazia Therapeutics Limited ADS | at 09:43:04 ET on NASDAQ | 2025-12-02
December 2, 2025 at 2:48 PM
liquiditynews.bsky.social
Trading Halted for $KZIA Kazia Therapeutics Limited ADS | at 09:38:04 ET on NASDAQ | Volatility Trading Pause | 2025-12-02
December 2, 2025 at 2:43 PM
stocktitan.net
#KZIA Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

https://www.stocktitan.net/news/KZIA/kazia-therapeutics-announces-pricing-of-50-0-million-private-hngjmmnia95w.html
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
SYDNEY, Dec. 2, 2025/ PRNewswire/-- Kazia Therapeutics Limited, an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities. Pursuant to the securities purchase agreement, the Company...
www.stocktitan.net
December 2, 2025 at 2:01 PM
handle.invalid
🚀 Exciting times for #KZIA! With FDA approval boosting confidence, Kazia Therapeutics is on the rise. Bullish indicators and a strong MACD suggest upward momentum, but watch that RSI! Consider a long position at $10.50, targeting $11.50-$12.00. Stay sharp! 📈 #Biotech
November 30, 2025 at 2:02 PM
handle.invalid
🚀 Exciting times for #KZIA! Trading at $10.59, it's breaking barriers with bullish momentum and strong technicals. With targets at $11.50 & $12.50, and a stop loss at $9.80, this could be a thrilling ride! Keep an eye on those clinical trial updates! 📈 #FeetrAI #Stocks
November 29, 2025 at 5:00 PM
handle.invalid
🚀 Exciting times for #KZIA! Trading at $10.13, it's riding a bullish wave with strong upward momentum. With a 10-day SMA of $8.02 and positive MACD, the technicals are hot! Consider going long with targets at $11 & $12. Stay sharp for any market shifts! 📈 #FeetrAI
November 27, 2025 at 8:00 PM
handle.invalid
🚀 Exciting times for #KZIA! Trading at $10.13 with bullish momentum, the 10-day SMA at $8.02 & 8-day EMA at $9.01 signal potential gains. MACD is positive, RSI at 59—room to grow! Consider a LONG position targeting $11-$12. Stay alert for market shifts! #FeetrAI #Stocks 📈
November 27, 2025 at 2:01 PM
stockquakes.com
#Trading #StockMarket

Wednesday November 26, 2025

See StockQuakes.substack.com

Top UP stock today is stock SMX, Smx Security Matters with a HUGE StockQuakes level of 14.4.

Top DOWN stock today is stock symbol KZIA, Kazia Therapeutics LTD with a LARGE negative StockQuakes level of -7.5.
StockQuakes | StockQuakes Team | Substack
Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.
StockQuakes.substack.com
November 27, 2025 at 2:46 AM
handle.invalid
🚀 Exciting times for #KZIA! Despite recent dips, bullish MACD and strong short-term moving averages hint at a potential rebound. 📈 Consider going long at $10.00, targeting $11.00 & $12.00 with a stop at $9.50. Moderate confidence in hitting the first target! #Stocks #FeetrAI
November 26, 2025 at 9:49 PM
handle.invalid
🚀 Exciting times for #KZIA! With a surge in volume and trading above key moving averages, bullish momentum is building. 📈 RSI hints caution, but MACD supports upward potential. Consider entering at $10.00 with targets at $11.50 & $12.50. Stop loss: $9.50. #FeetrAI
November 26, 2025 at 9:48 PM
handle.invalid
🚀 Exciting times for #KZIA! With a strong bullish momentum, it's trading at $11.33, well above its 10-day SMA of $8.16. Despite high RSI levels, the MACD supports further gains. Targeting $12.00 & $12.50 with a stop loss at $10.80. Stay alert for market shifts! 📈 #FeetrAI
November 26, 2025 at 8:01 PM
ginad.bsky.social
KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination
Source: Stocktwits
share.newsbreak.com/g0a34rhn
KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination - NewsBreak
The patient remains on therapy and under active clinical monitoring, the company said.In October, Kazia had announced that it observed an 86% reduction in
share.newsbreak.com
November 21, 2025 at 3:48 AM
smcapstrategist.bsky.social
Most searched small-cap stocks, Wed Nov 19th - #LAC #KZIA #RXRX #QUBT #SGML #SGML #SEMR #EOSE #NUVB #OLMA #DNN #AGIO #PLUG #SGBX #ONDS #IQ #EVH #CEP #CAAS #BORR #AMLX - More: crystalequityresearch.com/most-searche... - #smallcap
Most Searched, Wednesday November 19, 2025 – Crystal Equity Research
crystalequityresearch.com
November 20, 2025 at 12:08 AM
vitaminrush.bsky.social
Kazia Therapeutics reports immune complete response in TNBC

https://www.vitaminrush.com/268332/kazia-therapeutics-reports-immune-complete-response-in-tnbc/

SYDNEY, Nov. 19, 2025 /PRNewswire/ — Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today …
Kazia Therapeutics reports immune complete response in TNBC
SYDNEY, Nov. 19, 2025 /PRNewswire/ — Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests a profound radiologic response in a highly aggressive metastatic cancer subtype. This development builds upon Kazia’s October 2, 2025 announcement reporting an 86% reduction in tumor burden after only three weeks of treatment in the same patient. A PET/CT scan performed after approximately
www.vitaminrush.com
November 19, 2025 at 3:00 PM
stockmaster70.bsky.social
📢 Stocks Trending NOW: #TGT #TMC #PLUG #SEMR #KZIA #LOW #ADBE #TJX #AZI #U
November 19, 2025 at 2:20 PM
achwalter.bsky.social
#unverzüglich

#Mauerfall

Pressekonferenz am 09.11.1989

m.youtube.com/watch?v=kZiA...
Pressekonferenz DDR-Reiseregelung [09.11.1989]
YouTube video by BasicMasterReloaded
m.youtube.com
November 9, 2025 at 7:49 PM
biopharmcatalyst.bsky.social
$GNTA expands ANEMOCYTE partnership to commercialize scalable LVV plasmid DNA tech for advanced therapies. $NTLA $RNA $NBTX $ZBIO $KZIA $DYN $NMRA $OGN $NRXS

www.biopharmcatalyst.com/news/2025/ge...
Pre-Market Updates 10/27/25
export-download.canva.com
October 27, 2025 at 12:40 PM
stocktitan.net
#KZIA Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

https://www.stocktitan.net/news/KZIA/kazia-therapeutics-to-request-fda-type-c-meeting-to-discuss-overall-bcjf4ywyewqs.html
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
SYDNEY, Oct. 27, 2025/ PRNewswire/-- Kazia Therapeutics Limited today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food& Drug Administration to discuss overall survival findings in newly diagnosed glioblastoma patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the...
www.stocktitan.net
October 27, 2025 at 11:15 AM
stocktitan.net
#KZIA Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

https://www.stocktitan.net/news/KZIA/kazia-therapeutics-announces-collaboration-and-in-licensing-m05r32k80fd0.html
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
Kazia Therapeutics (NASDAQ: KZIA) on October 7, 2025 announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader program.The lead optimized compound, NDL2, is described as an advanced PD-L1 protein degrader currently in development and positioned as a novel approach in cancer immunotherapy.
www.stocktitan.net
October 7, 2025 at 12:31 PM
biopharmcatalyst.bsky.social
$KZIA: New ex vivo data shows paxalisib reduces metastatic burden in Stage IV HER2+ breast cancer. $RVMD $KALV $BDSX $APM $NRSN $RNA among pre-market movers.

www.biopharmcatalyst.com/news/2025/ka...
Pre-Market Updates 09/11/25
export-download.canva.com
September 11, 2025 at 12:40 PM